Roche   link
Lieu: Bâle

Domaine: Pharmacologie

Roche est le numéro 1 mondial de la biotechnologie, avec plusieurs produits biopharmaceutiques sur le marché. Plus de la moitié des composés du pipeline sont des produits biopharmaceutiques, ce qui permet à Roche de proposer des thérapies mieux ciblées.

Pharmacologie - Santé - 17.08
First and only FDA-approved subcutaneous treatment option for anti-aquaporin-4 antibody positive NMOSD that can be self-administered by a person with NMOSD or a caregiver every four weeks First and only approved therapy for NMOSD designed to target and inhibit interleukin-6 receptor activity, using novel recycling antibody technology Approval su
Pharmacologie - Santé - 10.08

In two clinical trials, Evrysdi improved motor function in people living with SMA over a broad spectrum of ages and levels of disease severity, including Types 1, 2, and 3 SMA

Pharmacologie - Santé - 28.05

Roche is also close to completing enrolment of a global randomised, double-blind, placebo-controlled phase III clinical trial of Actemra /RoActemra (tocilizumab) in hospitalised patients with severe COVID-19 pneumonia (COVACTA), with results expected this summer.

Pharmacologie - Santé - 21.01

Novel combination regimen includes first-in-class antibody-drug conjugate that specifically targets CD79b Targeted off-the-shelf treatment provides much-needed new option for people with relapsed or refractory diffuse large B-cell lymphoma Polivy approval is based on a phase Ib/II study, the first and only study showing improved response rates a

Pharmacologie - Santé - 13.12.2019

Roche today announced the Phase III IMspire150 study, in people with previously untreated BRAF V600 mutation-positive advanced melanoma, met its primary endpoint of progression-free survival (PFS). The study showed adding Tecentriq (atezolizumab) to Cotellic (cobimetinib) and Zelboraf (vemurafenib) helped to reduce the risk of disease worsening or death, compared to placebo plus Cotellic and Zelboraf.

Pharmacologie - Santé - 11.12.2019

Greatest improvement in invasive disease-free survival (iDFS) remains in patients at high risk of recurrence, such as those with lymph node-positive disease with a 28% reduction in the risk of recurrence or death, corresponding to an absolute iDFS benefit of 4.5% at six years With longer follow-up, treatment effect is seen regardless of h

Pharmacologie - Santé - 13.07

Second interim analysis of the STASEY study, including data from 193 patients, consistent with results from phase III HAVEN studies, with no new safety signals identified 1,2,3

Pharmacologie - Santé - 27.01

Application is being reviewed under FDA's Real-Time Oncology Review pilot programme Roche today announced the completion of a supplemental Biologics License Application (sBLA) submission to the US Food and Drug Administration (FDA) for Tecentriq (atezolizumab) in combination with Avastin (bevacizumab), for the treatment of people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.

Pharmacologie - Santé - 16.12.2019

All antitrust approvals required to close the transaction received. Roche and Spark Therapeutics, Inc.

Pharmacologie - Santé - 12.12.2019

Fixed-dose combination administered under the skin in just minutes, compared to hours with intravenous administration, significantly reducing time spent receiving treatment Phase III FeDeriCa study showed non-inferior pharmacokinetics and comparable efficacy and safety with the fixed-dose combination when compared to intravenous formulations Dat

Santé - Pharmacologie - 10.12.2019

Accu-Chek SugarView is the first app that determines blood glucose ranges by taking photos with the smartphone camera without the need of a blood glucose meter. It is designed to help non-insulin-dependent people with type 2 diabetes or pre-diabetes live healthier lives in-between doctors' visits.